Join
Live feed
·
PRReleasevia Quantisnow
Akebia Therapeutics Inc. logo

Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients

ByQuantisnow·Wall Street's wire, on your screen.
AKBA· Akebia Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKBA (Akebia Therapeutics Inc.) and more on Quantisnow.